OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United ...
OKYO Pharma Limited (NASDAQ: OKYO) is an emerging ophthalmology-focused biopharmaceutical company developing treatments for patients suffering from inflammatory eye conditions and ocular discomfort. The company’s strategy centers on targeted therapeutic candidates for corneal and anterior segment diseases, particularly conditions that involve chronic ocular inflammation and pain. Based on the company ...OKYO Pharma Limited (NASDAQ: OKYO) is an emerging ophthalmology-focused biopharmaceutical company developing treatments for patients suffering from inflammatory eye conditions and ocular discomfort. The company’s strategy centers on targeted therapeutic candidates for corneal and anterior segment diseases, particularly conditions that involve chronic ocular inflammation and pain. Based on the company description provided, OKYO maintains an early-stage R&D posture—supporting preclinical work and (in certain references) progressing toward clinical evaluation through regulatory clearances.
From a product and pipeline perspective, OKYO’s key programs include OK-101, designed to address dry eye disease, and OK-201, an investigational bovine adrenal medulla lipidated-peptide analogue intended for neuropathic ocular pain (NCP). The company’s development focus suggests an emphasis on differentiated mechanisms for ocular surface disease and pain pathways rather than broad-spectrum ophthalmic treatments.
Business-wise, OKYO is organized to run drug-development activities typical for a small public biotech: discovery and translational research, regulatory and clinical preparation, and ongoing evaluation of candidate safety/efficacy signals. The company operates from London, UK (55 Park Lane) and is led by CEO Robert J. Dempsey, with additional leadership participation from directors including Gary S. Jacob, PhD (described in leadership-related excerpts as transitioning within executive responsibilities).
In terms of operating scale, public disclosures referenced indicate a very small workforce (about 5 full-time employees, with LinkedIn indicating roughly 2–10 employees). That size is consistent with an early-stage biotech that relies on external expertise, clinical partners, and project-based resource allocation.
Financially, the company profile data provided shows characteristics consistent with an early-stage biopharma: limited or no revenue contribution in the metrics snapshot, and negative profitability indicators (e.g., negative returns on assets/equity and negative margins in the provided ratios). Financial figures such as enterprise value and liquidity-related ratios (e.g., current ratio above 1 in the snapshot) may reflect ongoing funding needs typical for pre-revenue or development-stage enterprises.
Cost and BOM (bill-of-materials) considerations for an R&D-driven company like OKYO typically include R&D labor and contractor spend, regulatory/clinical operations, manufacturing and formulation-related costs for investigational candidates, and ongoing compliance overhead required for maintaining public-company and drug-development processes. Specific line-item cost breakdowns were not provided, but the company’s focus and small headcount imply a lean internal cost structure with substantial spend directed toward development activities.
As a public company, OKYO also maintains corporate and investor communications, including disclosures and press releases such as announcements about share purchases by the chairman and updates related to annual reporting and cash position strengthening. Overall, OKYO’s “wishes” or intended trajectory, inferred from its pipeline and regulatory/clinical framing, is to progress its ophthalmic candidates toward clinical proof and, ultimately, therapeutic adoption for patients dealing with dry eye disease and neuropathic ocular pain.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-8.9M
-90.2%
-146.0%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-5.9M
-227.9%
-188.8%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.0%
—
+100.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
2.43x
+509.2%
+321.3%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
